Clinical trials: Central Nervous System Infections
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)
The purpose of this study is to see if it is safe and effective to give topotecan through a vein to treat HIV-infected patients with PML, an opportunistic (AIDS-related) infection caused by a virus that infects brain tissue and…
- Trial name
- NCT00002395
- Testing
- Topotecan
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- SmithKline Beecham
Virus Diseases
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
The purpose of this study is to evaluate the 1 year immunogenicity persistence of Rabipur in children 6-17 years of age, and compare the Zagreb regimen with the Essen regimen.
- Trial name
- NCT03192371
- Testing
- Rabipur
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neuralgia, Shingles
Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia
The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with painful post-herpetic neuralgia (PHN).
- Conditions
- Neuralgia, Shingles, Peripheral Nervous System Disease
- Trial name
- NCT00099528
- Testing
- REN-1654
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- Renovis
Meningococcal Disease
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
The primary purpose of this study is to evaluate the persistence of bactericidal antibodies in children of approximately 22 to 45 months of age previously enrolled in the V59P22 study (NCT00667602) who received Novartis MenACWY…
- Trial name
- NCT01345721
- Testing
- MenACWY-CRM
- Where
- 11 sites in Germany
- Volunteers
- 205 people
- Sponsor
- Novartis Vaccines
Japanese Encephalitis
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.
- Trial name
- NCT01900444
- Testing
- IMOJEV
- Where
- 8 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Meningitis
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)
This observer-blind, randomized, active controlled trial will be conducted among 2-29 year olds in two sites (Mali and The Gambia).
- Trial name
- NCT03964012
- Testing
- NmCV-5, Menactra
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
AIDS Dementia Complex, HIV Infections
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
The purpose of this study is to see if adding stavudine (d4T) to anti-HIV drug regimens (with or without zidovudine, ZDV) can improve symptoms of AIDS Dementia Complex (ADC, problems involving the brain or spinal cord) in…
- Trial name
- NCT00002246
- Testing
- Stavudine
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Ventilators, Mechanical, Stroke
Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
The goal of this observational study is to compare pulmonary health parameter measurements from the VQm PHM™ to existing clinical measurements.
- Conditions
- Ventilators, Mechanical, Stroke, COPD, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06147674
- Testing
- VQm Pulmonary Health Monitor™
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 150 people
- Sponsor
- Rostrum Medical Innovations Inc.
Respiratory Tract Infections, Urinary Tract Infections
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- SEPSIS-SHIELD (NCT04094818)
- Testing
- TriVerity
- Where
- 26 sites in United States, Greece
- Volunteers
- 1,441 people
- Sponsor
- Inflammatix
Increased Lordosis/Scoliosis, Hyporeflexia
Biomarker for Duchenne Muscular Dystrophy
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
- Conditions
- Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness
- Trial name
- BioDuchenne (NCT02994030)
- Where
- 12 sites in Albania, Egypt and 6 more
- Volunteers
- 103 people
- Sponsor
- CENTOGENE GmbH Rostock
Diphtheria, Tetanus
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
PRIMARY OBJECTIVES To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3 To…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT01546909
- Testing
- Diphtheria, tetanus, polio and pertussis vaccination
- Where
- 45 sites in France
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
AIDS Dementia Complex, HIV Infections
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.
- Trial name
- NCT00002163
- Testing
- Abacavir sulfate
- Where
- 9 sites in United States, Canada
- Sponsor
- Glaxo Wellcome
Pharyngitis, Pain
Ambroxol Spray Sore Throat Study
The development of a new Ambroxol spray formulation for the treatment of sore throat pain associated with acute pharyngitis requires an initial phase II study to be conducted in order to select the most appropriate dose for pain…
- Trial name
- NCT01361802
- Testing
- Ambroxol Spray
- Where
- 15 sites in South Africa
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Meningococcal Meningitis, Tetanus
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine.
- Conditions
- Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis
- Trial name
- NCT00355121
- Testing
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 26 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hydrocephalus
Bactiseal Catheter Safety Registry Study
Research Purpose: This study aims to continuously evaluate the safety of subjects implanted with a catheter (trade name: Bactiseal) produced by Integra LifeSciences Production Corporation.
- Trial name
- NCT06276543
- Testing
- antibiotic-impregnated catheter
- Where
- 8 sites in China
- Volunteers
- 200 people
- Sponsor
- Integra LifeSciences Corporation
Meningitis, Meningococcal Meningitis
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
The aim of this study is to provide information on the persistence of bactericidal antibodies following Menactra booster vaccination in study MTA77 ( NCT01442675).
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02633787
- Testing
- Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 4 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
The purpose of the study is to evaluate the safety and immunogenicity of a novel Venezuelan Equine Encephalitis virus (VEEV) vaccine (V4020) for the first time in humans compared to placebo when administered by subcutaneous or…
- Trial name
- VEEV (NCT07088822)
- Testing
- V4020
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Medigen, Inc.
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Equine Encephalitis
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
- Trial name
- NCT04131595
- Testing
- MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)
This is a study to assess the safety, tolerability, and immunogenicity of V419 (PR5I) when administered as an infant series at 2, 4, and 6 months of age followed by a toddler dose of DAPTACEL™, Prevnar 13™ and PedvaxHIB™ at 15…
- Trial name
- NCT01337167
- Testing
- V419, DAPTACEL™, PedvaxHIB™
- Volunteers
- 1,473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC